PRELAJ, ARSELA
 Distribuzione geografica
Continente #
NA - Nord America 2.686
EU - Europa 1.869
AS - Asia 1.847
SA - Sud America 386
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 56
OC - Oceania 2
Totale 6.903
Nazione #
US - Stati Uniti d'America 2.611
RU - Federazione Russa 688
IT - Italia 667
SG - Singapore 554
CN - Cina 471
BR - Brasile 322
VN - Vietnam 270
KR - Corea 137
HK - Hong Kong 95
DE - Germania 83
FI - Finlandia 75
JP - Giappone 75
BD - Bangladesh 73
FR - Francia 70
NL - Olanda 63
GB - Regno Unito 45
CA - Canada 42
SE - Svezia 42
IN - India 34
AT - Austria 32
ID - Indonesia 32
IE - Irlanda 26
AR - Argentina 21
CI - Costa d'Avorio 14
ES - Italia 14
PH - Filippine 14
EC - Ecuador 13
IQ - Iraq 13
PL - Polonia 11
MX - Messico 10
TR - Turchia 10
CO - Colombia 9
UA - Ucraina 9
ZA - Sudafrica 9
DK - Danimarca 8
SA - Arabia Saudita 8
AZ - Azerbaigian 7
BE - Belgio 7
PK - Pakistan 7
TH - Thailandia 7
UZ - Uzbekistan 7
JM - Giamaica 6
KG - Kirghizistan 6
MA - Marocco 6
BJ - Benin 5
CH - Svizzera 5
KE - Kenya 5
PY - Paraguay 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
HN - Honduras 4
UY - Uruguay 4
BO - Bolivia 3
EG - Egitto 3
IL - Israele 3
NG - Nigeria 3
PT - Portogallo 3
SN - Senegal 3
BH - Bahrain 2
CL - Cile 2
DO - Repubblica Dominicana 2
EE - Estonia 2
HR - Croazia 2
JO - Giordania 2
KZ - Kazakistan 2
LB - Libano 2
NO - Norvegia 2
NP - Nepal 2
RS - Serbia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GF - Guiana Francese 1
GT - Guatemala 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
LT - Lituania 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
MQ - Martinica 1
MU - Mauritius 1
MY - Malesia 1
NA - Namibia 1
Totale 6.843
Città #
Ashburn 484
Singapore 347
San Jose 270
Chandler 187
Milan 169
Santa Clara 160
Council Bluffs 153
Seoul 131
Hefei 115
Fairfield 105
Moscow 95
Boardman 90
Hong Kong 89
The Dalles 88
Beijing 77
Ho Chi Minh City 73
Rome 65
Tokyo 64
Helsinki 59
Hanoi 53
Los Angeles 52
Houston 49
Lauterbourg 43
Cambridge 42
Seattle 42
Wilmington 34
Woodbridge 31
New York 30
Amsterdam 29
North Charleston 29
São Paulo 27
Dublin 26
Vienna 26
Dallas 23
Lawrence 23
Munich 23
San Diego 22
Frisco 21
Buffalo 17
Kent 17
Naples 17
Redmond 17
Ann Arbor 16
Dong Ket 16
Atlanta 15
Frankfurt am Main 15
Toronto 15
Jakarta 14
Abidjan 13
Nuremberg 13
Palermo 13
Princeton 13
Da Nang 12
Las Vegas 12
Medford 12
Rio de Janeiro 12
Haiphong 11
Chicago 10
Redwood City 10
Salt Lake City 10
Turin 10
Genoa 9
Lappeenranta 9
London 9
Salvador 9
Madrid 8
Manila 8
Orem 8
Philadelphia 8
Warsaw 8
Baku 7
Bologna 7
Changsha 7
Figino 7
Johannesburg 7
Stockholm 7
Tashkent 7
Turku 7
Bari 6
Bishkek 6
Chūō 6
Curitiba 6
Montreal 6
Newark 6
Phoenix 6
Porto Alegre 6
Americana 5
Brasília 5
Brooklyn 5
Brussels 5
Catania 5
Chennai 5
Copenhagen 5
Cotonou 5
Düsseldorf 5
Goiânia 5
Guangzhou 5
Guayaquil 5
Hangzhou 5
Miami 5
Totale 4.006
Nome #
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients 261
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review 257
Abstract PO-065: Artificial intelligence to improve selection for NSCLC patients treated with immunotherapy 239
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 191
Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort 188
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation 181
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records 180
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy 180
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 177
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy 176
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis 174
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? 169
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis 167
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 165
Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma 158
178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients 156
MetaLung: Towards a Secure Architecture for Lung Cancer Patient Care on the Metaverse 155
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 147
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 145
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation 144
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project 142
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis 142
An ensemble approach to predict immunotherapy efficacy in non-small cell lung cancer using digital pathology 139
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 139
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis 138
Exploring the role of respiratory microbiome in lung cancer: A systematic review 134
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 131
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 129
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer 123
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study 122
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer 121
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy 118
Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development 117
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 112
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease 111
Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients 110
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 109
Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib 102
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 101
Novel emerging molecular targets in non-small cell lung cancer 101
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors 100
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 98
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 95
SMO mutations confer poor prognosis in malignant pleural mesothelioma 92
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 88
Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of EGFR-mutated advanced NSCLC patients 71
Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer 55
Aiding data retrieval in clinical trials with large language models: The APOLLO 11 Consortium in advanced lung cancer patients 48
Trustworthy assessment of 2D model for lung CT scans 45
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer 41
Automatic Cough Analysis for Non-Small Cell Lung Cancer Detection 31
A Contrastive Variational AutoEncoder for NSCLC Survival Prediction with Missing Modalities 31
Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group 23
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours 19
Cost-effectiveness models of non–small cell lung cancer: A systematic literature review 15
Totale 6.903
Categoria #
all - tutte 21.569
article - articoli 20.194
book - libri 0
conference - conferenze 1.375
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.138


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022233 0 27 26 11 11 27 7 17 11 12 40 44
2022/2023362 40 49 10 45 48 32 4 27 58 21 20 8
2023/2024280 13 29 12 14 11 20 7 28 29 21 19 77
2024/2025917 32 19 29 40 145 88 29 73 115 56 129 162
2025/20264.321 593 678 228 334 241 165 562 258 304 417 147 394
2026/2027307 142 165 0 0 0 0 0 0 0 0 0 0
Totale 6.903